Skip to content

Waters Corporation WAT Waters Advanced Diagnostics — Goodwill Acquired

Similar metrics at other companies

Labcorp Holdings logo
LHDiagnostics — Goodwill acquired, excluding measurement period adjustments
$146.6M
Xylem logo
XYLWater Solutions and Services — Goodwill, Acquired During Period
$3M
Xylem logo
XYLApplied Water — Goodwill, Acquired During Period
$0
Revvity logo
RVTYDiagnostics — Goodwill, Acquisition
$0
Veralto logo
VLTOWater Quality — Goodwill, Acquired During Period
$5.75M
Ecolab logo
ECLWater Services — Goodwill Acquired
$276.35M+851%

Other financials

Income statement

See full
Revenue$1.3B+91.4%
Gross profit$569.5M+8.6%
Operating income-$47.0M-131%
Net income-$72.0M-160%
EPS (diluted)-$0.87-143%

Balance sheet

See full
Cash & equivalents$462.0M+20.7%
Total debt$5.2B+263%
Total equity$15.3B+679%
Total assets$24.5B+434%

Cash flow

See full
Operating cash flow-$3.0M-101%
CapEx$39.0M+50.0%
Free cash flow-$42.0M-118%

Valuation

See full
Market cap$36.76B+78.1%
Enterprise value$41.51B+92.6%
P/E81.8×+50.6×
P/S9.8×+3.0×

Profitability

See full
Gross margin59.3%-0.1pp
Operating margin16%-12.3pp
Net margin11.9%-10.1pp
FCF margin7%-13.8pp

Returns & leverage

See full
Return on equity5.2%-35.6pp
Debt / equity0.3×-0.4×
Current ratio1.8×0.0×

Where this comes from

Reported directly by Waters Corporation in its filing.

Tagged under the XBRL concept us-gaap:GoodwillAcquiredDuringPeriod.

The official record: Waters Corporation’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Waters Corporation's waters advanced diagnostics — goodwill acquired.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Waters Corporation's waters advanced diagnostics — goodwill acquired?
Waters Corporation (WAT) reported waters advanced diagnostics — goodwill acquired of $3.28B in Q1 2026.
What does waters advanced diagnostics — goodwill acquired mean?
Captures the value of goodwill recognized specifically from business combinations completed during the current reporting period for the Advanced Diagnostics segment. It represents the excess purchase price paid for new diagnostic-related entities over their net identifiable assets.